vs

Side-by-side financial comparison of Corteva (CTVA) and Sempra (SRE). Click either name above to swap in a different company.

Corteva is the larger business by last-quarter revenue ($3.9B vs $3.3B, roughly 1.2× Sempra). Sempra runs the higher net margin — 10.7% vs -14.1%, a 24.8% gap on every dollar of revenue. On growth, Sempra posted the faster year-over-year revenue change (6.9% vs -1.7%). Corteva produced more free cash flow last quarter ($4.2B vs $-2.2B). Over the past eight quarters, Sempra's revenue compounded faster (-5.8% CAGR vs -6.7%).

Corteva, Inc. is an American company devoted to products for seeds and crop protection, including herbicides, insecticides, fungicides, and biologicals that are sold in 110 countries. The company's name combines "cor" with "teva". It is headquartered in Indianapolis, Indiana. Corteva sells a large portion of their seeds under the Pioneer Hi-Bred International brand.

Sempra is a North American public utility holding company based in San Diego, California. The company is one of the largest utility holding companies in the United States with nearly 40 million consumers.

CTVA vs SRE — Head-to-Head

Bigger by revenue
CTVA
CTVA
1.2× larger
CTVA
$3.9B
$3.3B
SRE
Growing faster (revenue YoY)
SRE
SRE
+8.7% gap
SRE
6.9%
-1.7%
CTVA
Higher net margin
SRE
SRE
24.8% more per $
SRE
10.7%
-14.1%
CTVA
More free cash flow
CTVA
CTVA
$6.4B more FCF
CTVA
$4.2B
$-2.2B
SRE
Faster 2-yr revenue CAGR
SRE
SRE
Annualised
SRE
-5.8%
-6.7%
CTVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTVA
CTVA
SRE
SRE
Revenue
$3.9B
$3.3B
Net Profit
$-552.0M
$352.0M
Gross Margin
42.4%
Operating Margin
-13.6%
7.2%
Net Margin
-14.1%
10.7%
Revenue YoY
-1.7%
6.9%
Net Profit YoY
-1246.3%
-47.9%
EPS (diluted)
$-0.80
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTVA
CTVA
SRE
SRE
Q4 25
$3.9B
$3.3B
Q3 25
$2.6B
$2.8B
Q2 25
$6.5B
$2.7B
Q1 25
$4.4B
$3.7B
Q4 24
$4.0B
$3.1B
Q3 24
$2.3B
$2.6B
Q2 24
$6.1B
$2.5B
Q1 24
$4.5B
$3.7B
Net Profit
CTVA
CTVA
SRE
SRE
Q4 25
$-552.0M
$352.0M
Q3 25
$-320.0M
$95.0M
Q2 25
$1.3B
$473.0M
Q1 25
$652.0M
$917.0M
Q4 24
$-41.0M
$676.0M
Q3 24
$-524.0M
$649.0M
Q2 24
$1.1B
$725.0M
Q1 24
$419.0M
$812.0M
Gross Margin
CTVA
CTVA
SRE
SRE
Q4 25
42.4%
Q3 25
37.2%
Q2 25
54.6%
Q1 25
47.0%
Q4 24
37.3%
Q3 24
32.7%
Q2 24
52.3%
Q1 24
43.2%
Operating Margin
CTVA
CTVA
SRE
SRE
Q4 25
-13.6%
7.2%
Q3 25
-14.1%
10.6%
Q2 25
27.9%
17.3%
Q1 25
17.7%
21.5%
Q4 24
2.2%
35.0%
Q3 24
-27.2%
12.9%
Q2 24
21.9%
18.8%
Q1 24
10.7%
22.7%
Net Margin
CTVA
CTVA
SRE
SRE
Q4 25
-14.1%
10.7%
Q3 25
-12.2%
3.4%
Q2 25
20.4%
17.5%
Q1 25
14.8%
24.9%
Q4 24
-1.0%
22.0%
Q3 24
-22.5%
25.3%
Q2 24
17.2%
29.2%
Q1 24
9.3%
22.0%
EPS (diluted)
CTVA
CTVA
SRE
SRE
Q4 25
$-0.80
$0.53
Q3 25
$-0.47
$0.12
Q2 25
$1.92
$0.71
Q1 25
$0.95
$1.39
Q4 24
$-0.05
$1.04
Q3 24
$-0.76
$1.00
Q2 24
$1.51
$1.12
Q1 24
$0.60
$1.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTVA
CTVA
SRE
SRE
Cash + ST InvestmentsLiquidity on hand
$4.5B
$29.0M
Total DebtLower is stronger
$1.7B
$29.0B
Stockholders' EquityBook value
$24.1B
$31.6B
Total Assets
$42.8B
$110.9B
Debt / EquityLower = less leverage
0.07×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTVA
CTVA
SRE
SRE
Q4 25
$4.5B
$29.0M
Q3 25
$2.6B
$5.0M
Q2 25
$2.1B
$155.0M
Q1 25
$2.0B
$1.7B
Q4 24
$3.2B
$1.6B
Q3 24
$2.5B
$560.0M
Q2 24
$2.0B
$228.0M
Q1 24
$1.7B
$606.0M
Total Debt
CTVA
CTVA
SRE
SRE
Q4 25
$1.7B
$29.0B
Q3 25
$1.7B
$29.0B
Q2 25
$1.7B
$34.9B
Q1 25
$1.8B
$33.3B
Q4 24
$2.0B
$31.6B
Q3 24
$2.0B
$31.0B
Q2 24
$2.5B
$29.0B
Q1 24
$2.5B
$29.5B
Stockholders' Equity
CTVA
CTVA
SRE
SRE
Q4 25
$24.1B
$31.6B
Q3 25
$25.2B
$31.2B
Q2 25
$25.9B
$31.7B
Q1 25
$24.3B
$31.6B
Q4 24
$23.8B
$31.2B
Q3 24
$24.7B
$29.7B
Q2 24
$25.2B
$29.5B
Q1 24
$24.8B
$29.1B
Total Assets
CTVA
CTVA
SRE
SRE
Q4 25
$42.8B
$110.9B
Q3 25
$42.2B
$106.9B
Q2 25
$41.8B
$99.9B
Q1 25
$42.1B
$99.0B
Q4 24
$40.8B
$96.2B
Q3 24
$41.9B
$93.7B
Q2 24
$41.5B
$90.5B
Q1 24
$43.6B
$89.6B
Debt / Equity
CTVA
CTVA
SRE
SRE
Q4 25
0.07×
0.92×
Q3 25
0.07×
0.93×
Q2 25
0.07×
1.10×
Q1 25
0.07×
1.05×
Q4 24
0.08×
1.01×
Q3 24
0.08×
1.04×
Q2 24
0.10×
0.98×
Q1 24
0.10×
1.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTVA
CTVA
SRE
SRE
Operating Cash FlowLast quarter
$4.4B
$1.2B
Free Cash FlowOCF − Capex
$4.2B
$-2.2B
FCF MarginFCF / Revenue
106.2%
-67.7%
Capex IntensityCapex / Revenue
5.7%
104.0%
Cash ConversionOCF / Net Profit
3.38×
TTM Free Cash FlowTrailing 4 quarters
$2.8B
$-6.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTVA
CTVA
SRE
SRE
Q4 25
$4.4B
$1.2B
Q3 25
$193.0M
$1.1B
Q2 25
$947.0M
$784.0M
Q1 25
$-2.1B
$1.5B
Q4 24
$4.2B
$1.4B
Q3 24
$130.0M
$1.0B
Q2 24
$451.0M
$669.0M
Q1 24
$-2.6B
$1.9B
Free Cash Flow
CTVA
CTVA
SRE
SRE
Q4 25
$4.2B
$-2.2B
Q3 25
$36.0M
$-1.5B
Q2 25
$829.0M
$-1.5B
Q1 25
$-2.2B
$-854.0M
Q4 24
$4.0B
$-1.1B
Q3 24
$-24.0M
$-913.0M
Q2 24
$337.0M
$-1.2B
Q1 24
$-2.8B
$-82.0M
FCF Margin
CTVA
CTVA
SRE
SRE
Q4 25
106.2%
-67.7%
Q3 25
1.4%
-52.6%
Q2 25
12.8%
-56.3%
Q1 25
-49.9%
-23.2%
Q4 24
100.4%
-35.4%
Q3 24
-1.0%
-35.5%
Q2 24
5.5%
-49.4%
Q1 24
-61.4%
-2.2%
Capex Intensity
CTVA
CTVA
SRE
SRE
Q4 25
5.7%
104.0%
Q3 25
6.0%
92.9%
Q2 25
1.8%
85.3%
Q1 25
2.1%
63.5%
Q4 24
4.6%
79.9%
Q3 24
6.6%
75.3%
Q2 24
1.9%
76.4%
Q1 24
3.3%
52.3%
Cash Conversion
CTVA
CTVA
SRE
SRE
Q4 25
3.38×
Q3 25
11.68×
Q2 25
0.72×
1.66×
Q1 25
-3.23×
1.62×
Q4 24
2.02×
Q3 24
1.57×
Q2 24
0.43×
0.92×
Q1 24
-6.23×
2.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTVA
CTVA

Corn$1.4B35%
Herbicides$1.1B27%
Insecticides$488.0M12%
Fungicides$272.0M7%
Biologicals$191.0M5%
Soybean$164.0M4%
Other$160.0M4%
Otheroilseeds$94.0M2%

SRE
SRE

Segment breakdown not available.

Related Comparisons